Inovio Pharmaceuticals, Inc. (INO)
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing DNA-based immunotherapies and vaccines for infectious diseases, cancer, and other serious health conditions. Established in 2001, the company advances its research through proprietary DNA delivery technology and seeks to create innovative solutions to address unmet medical needs worldwide.
Company News
Arch Therapeutics is developing innovative self-assembling barrier technologies for interventional wound care, focusing on advanced hemostasis and sealant solutions across multiple medical applications.
Both biotechs have been struggling for a while, but there might be some hope for them.
Stephens initiated coverage on INOVIO Pharmaceuticals Inc (NASDAQ:INO), noting the company’s diversified clinical pipeline of therapeutic and vaccine candidates, which the company is looking to advance eight additional clinical-stage candidates. The analyst writes that the FDA considered lead program INO-3107 Phase 1/2 clinical trials sufficient for the Accelerated Approval Program. If approved, INO-3107 could be the first non-surgical treatment for recurrent respiratory papillomatosis (RRP). RRP is a rare chronic disease caused by the human papillomavirus. In RRP, wart-like tumors grow on and around vocal cords. FDA marketing application submission for INO-3107 ...Full story available on Benzinga.com
Equillium (EQ) delivered earnings and revenue surprises of 52.94% and 16.82%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
